Q2 2024 · 13F-HR
ACUTA CAPITAL PARTNERS, LLCholdings as filed
Filed 2024-08-14 · accession 0001104659-24-089377
$118.7M
Reported value
33
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $19.0M | 16.0% | 2,771,130 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $9.3M | 7.83% | 397,698 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $8.3M | 7.02% | 110,400 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $7.5M | 6.32% | 212,500 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $6.8M | 5.73% | 164,431 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS | $6.1M | 5.10% | 135,141 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $5.4M | 4.54% | 250,370 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $5.2M | 4.40% | 2,330,937 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $5.2M | 4.35% | 133,000 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $4.8M | 4.07% | 72,100 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $4.3M | 3.66% | 27,500 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $3.5M | 2.92% | 269,614 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMA | $3.4M | 2.86% | 78,700 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC. COMMON STOCK | $3.4M | 2.83% | 163,000 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $3.3M | 2.82% | 1,663,000 | Common | SOLE |
| 21833P301 | CRBP | CORBUS PHARMACEUTICALS HOLDI | $2.9M | 2.46% | 64,500 | Common | SOLE |
| 00032Q104 | WHWK | AADI BIOSCIENCES INC | $2.7M | 2.27% | 1,849,402 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $2.6M | 2.19% | 199,433 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $2.5M | 2.12% | 369,280 | Common | SOLE |
| 589492107 | MREO | MEREO BIOPHARMA GROUP PL-ADR | $2.4M | 2.05% | 677,000 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $2.3M | 1.96% | 42,200 | Common | SOLE |
| G4444H101 | BBOT | HELIX ACQUISITION CORP II | $1.8M | 1.53% | 177,836 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $1.7M | 1.45% | 4,000 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $774,800 | 0.65% | 260,000 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $737,100 | 0.62% | 45,000 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $678,720 | 0.57% | 96,000 | Common | SOLE |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $496,650 | 0.42% | 46,200 | Common | SOLE |
| 75383L102 | RAPP | RAPPORT THERAPEUTICS INC | $465,200 | 0.39% | 20,000 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA CO NV | $432,225 | 0.36% | 22,500 | Common | SOLE |
| 52187K200 | CYPH | LEAP THERAPEUTICS INC | $382,200 | 0.32% | 195,000 | Common | SOLE |
| 15117F807 | CLRBUSD | CELLECTAR BIOSCIENCES INC. | $176,250 | 0.15% | 70,500 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $100,750 | 0.08% | 250 | PUT | SOLE |
| 67080N119 | NUVB/WS | NUVATION BIO INC -CW27 | $14,533 | 0.01% | 90,832 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.